Sonata Therapeutics
Erik Hett serves as Chief Technology Officer at Sonata Therapeutics since March 2022 and is an Advisory Board Member for both Bunker Hill Community College's Division of Workforce & Economic Development and Tufts University since January 2020 and August 2019, respectively. Prior experience includes leadership roles at Merck as Senior Director and Director of Experimental and Chemical Biology and leading teams at Biogen and Pfizer. Erik's research background includes a Postdoctoral Fellowship at Massachusetts General Hospital and multiple affiliations with Harvards institutions. Educational qualifications include a PhD in Immunology and Infectious Diseases from Harvard, an MPH from Yale, and a B.S. from Montana State University-Bozeman, complemented by a certificate in Disruptive Strategy from Harvard Business School Online.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.